Drawing for SENDA

USPTO serial 90206856

SENDA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
DUBRAY, KATHERINE M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SENDA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christina M. Licursi

Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206United States

Goods and services

ClassDescriptionStatusFirst use
005Therapeutic preparations to modulate metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use; therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolismACTIVE—
042Research and development in the field of computational biology, biotechnology and pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 15, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 15, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 2, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 30, 2023EX4GSOU EXTENSION 4 GRANTED—
Nov 30, 2023EXT4SOU EXTENSION 4 FILED—
Nov 30, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 29, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 27, 2023EX3GSOU EXTENSION 3 GRANTED—
Apr 27, 2023EXT3SOU EXTENSION 3 FILED—
Apr 27, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 14, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 12, 2022EX2GSOU EXTENSION 2 GRANTED—
Dec 12, 2022EXT2SOU EXTENSION 2 FILED—
Dec 12, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 15, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 13, 2022EX1GSOU EXTENSION 1 GRANTED—
Jun 13, 2022EXT1SOU EXTENSION 1 FILED—
Jun 13, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 14, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 19, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 19, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 29, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 10, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 12, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 11, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 11, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 13, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2021DOCKASSIGNED TO EXAMINER—
Dec 9, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Nov 3, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 28, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance